Please show a full comparison of all four treatments available in Canada?

Feature

SUBLOCADE (buprenorphine XR inj.)

Buprenorphine / Naloxone (Suboxone etc.)

Methadone

Kadian / SROM (slow-release oral morphine)

Drug class / type

Partial μ-agonist, long-acting depot

Partial μ-agonist (± naloxone)

Full μ-agonist

Full μ-agonist (slow-release morphine)

Indication for OUD

Indicated for moderate–severe OUD in adults already induced on transmucosal bupe; monthly SC injection.HRES PDF+1

First-line OAT for OUD (Canada).Province of British Columbia+1

First-line OAT, esp. when bupe not suitable or ineffective.CAMH+1

Off-label for OUD; third-line after bupe and methadone; requires extra regulatory steps.CAMH+1

Dosing / route

Monthly SC depot injection (e.g. 100–300 mg), given by HCP only; no take-home.HRES PDF+1

Daily SL/BUCC film/tablet; often take-home once stable.

Daily oral liquid (or tabs); often witnessed dosing, especially early.bccdc.ca+1

Daily oral capsules; typically witnessed ingestion for OUD because of diversion/overdose risk.CAMH+1

Pharmacology / safety

Partial agonist with ceiling on respiratory depression; long, steady plasma levels from depot.sublocade.com+1

Partial agonist; ceiling effect; shorter-acting, daily peaks/troughs.CAMH+1

Full agonist; higher overdose risk (esp. co-sedatives, high dose, QTc issues).bccdc.ca+1

Full agonist; overdose risk similar to other long-acting opioids; careful titration and monitoring required.CAMH+1

Place in guidelines (Canada)

Considered one form of buprenorphine OAT, used after stabilization on SL bupe; various provincial manuals give specific criteria and informed-consent guidance.Manitoba Physicians & Surgeons+1

Preferred first-line where feasible (national guideline and BC guideline).Province of British Columbia+1

Alternative first-line when bupe not appropriate or fails.CAMH+1

Alternative / third-line when bupe and methadone have failed or are contraindicated.CAMH+1

Diversion risk

Very low (no take-home supply; depot in tissue).

Moderate–low; film/tablets can be diverted but less reinforcing than full agonists; naloxone discourages injection.CAMH

Moderate–high; liquid/full agonist; needs structured dispensing.bccdc.ca+1

High if not tightly controlled (full agonist caps can be chewed/crushed/injected).CAMH+1

Logistics / burden

Monthly clinic or OAT visit; requires provider trained and set up to give depot bupe; no daily pharmacy line-ups.Manitoba Physicians & Surgeons+1

Start-up can be done outpatient, sometimes at home with support; pharmacy contact varies (from daily to weekly/monthly pickups as trust builds).Province of British Columbia+1

Usually daily observed dosing (esp. in first months), ECG/QTc considerations; more rigid pharmacy schedule.bccdc.ca+1

Daily witnessed dosing almost always; special exemption paperwork; usually managed in specialized OAT clinics.CAMH+1

Advantages vs Kadian (from a peer-support lens)

• No daily pills or pharmacy lines • Strong diversion protection • Steady levels → less yo-yo withdrawal/craving • Partial agonist safety profile • Fits well with “freeing head-space” for recovery work.sublocade.com+1

• First-line, broad evidence base • Flexible dosing and easier to adjust • Take-homes possible • Partial agonist safety and familiarity.CAMH+1

• Powerful full agonist for people who simply don’t stabilize on bupe • Huge evidence base for OAT • Can be titrated to high tolerance populations (e.g., heavy fentanyl users).metaphi.ca+1

• Option for people who fail or can’t tolerate bupe/methadone • Full-agonist effect some patients find more “holding” • May improve retention for select methadone-intolerant patients.CAMH+1

Main drawbacks vs Kadian

• Requires someone willing/able to attend monthly injections • Harder to “fine-tune” dose day-to-day once injected • Access and cost/coverage can be limiting.CDA AMC+1

• Still daily med routine and potential for diversion • Some people on heavy fentanyl find bupe “not strong enough” or have induction problems.metaphi.ca+1

• Higher overdose/QTc risk; tight monitoring; stigma from “methadone clinic” structure • Daily pharmacy often feels like a leash for people working or parenting.bccdc.ca+1

• Highest diversion and overdose risk of the four • Regulatory hoops (Section 56 exemption etc.) • Off-label for OUD, thinner evidence base, guidelines explicitly say third-line.CAMH+1

“Best fit” cases (high-level, not medical advice)

People already on bupe who: want to get off the daily-med treadmill; have diversion concerns; chaotic life that makes daily pharmacy hard; can show up once a month.

First-time OAT starts; people who can manage daily meds and want flexibility and eventual take-homes.

Very high tolerance, long fentanyl history, or repeated bupe non-response; can handle daily structure and monitoring.

Niche: bupe + methadone both failed or not tolerated; managed by experienced OAT prescriber in a structured clinic.